



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
10793/50

Application Number
10/029,926

Filing Date
December 31, 2001

Examiner

Art Unit
1646

Invention Title
**SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE
CANCER THERAPY**

Inventor(s)
HAGAY, et al.

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the
United States Postal Service with sufficient postage as first class mail in an envelope
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-
1450 on

Date: 4/23/04


By: Kathryn M. Lumb
Kathryn M. Lumb (Reg. No. 46,885)

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
4. The Commissioner is hereby authorized to charge payment of the 37 C.F.R. § 1.17(p) (submission of an information disclosure statement under § 1.97(c)) fee of **\$180.00** to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**. The Commissioner is also authorized to charge any additional fees or credit any overpayment in connection with this paper to Deposit Account No. 11-0600.

Dated: 4/23/04

By: Kathryn M. Lumb
Kathryn M. Lumb (Reg. No. 46,885)
KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)
CUSTOMER NO. 26646

04/27/2004 HVUJH61 00000136 110600 10029926
01 FC:1806 180.00 DA



**SUPPLEMENTARY INFORMATION
DISCLOSURE STATEMENT BY
APPLICANT PTO-1449**

ATTY. DOCKET NO.
10793/50

SERIAL NO.
10/029,926

APPLICANT
HAGAY et al.

FILING DATE
December 31, 2001

GROUP
1646

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,716,836	February 10, 1998	Suiko			
	5,720,954	February 24, 1998	Hudziak, et al.			
	6,312,694	November 6, 2001	Thorpe, et al.			
	2002-0058034	May 16, 2002	Manjunath, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Huo, et al., "Adhesion molecules and atherogenesis," Acta Physiol Scand. 2001, Vol. 173, pp. 35-43
	Kamiyama, et al., "Inhibition of platelet GPIIb/IIIa binding to fibrinogen by serum factors: Studies of circulating immune complexes and platelet antibodies in patients with hemophilia, immune thrombocytopenic purpura, human immunodeficiency virus - related immune thrombocytopenic purpura, and systemic lupus erythematosus," J. Lab Clin. Med., (1991) Vol. 117, No. 3, pp. 209-217
	Libby, "Atherosclerosis: The New View," Scientific American, May 2002, pp. 28-37
	Ma, et al., "Obligatory Requirement of Sulfation for P-Selectin Binding to Human Salivary Gland Carcinoma Acc-M Cells and Breast Carcinoma ZR-75-30 Cells," Journal of Immunology, 2002, Vol. 168, pp. 1690-1696.
	Malmberg, et al., "BIAcore as a tool in antibody engineering," Journal of Immunological Methods, 1995, Vol. 183, pp. 7-13
	Michelson, et al., "Partial Characterization of a Binding Site For von Willebrand Factor on Glycocalicin," Blood, January 1986, Vol. 67, No. 1, pp. 19-26
	Myszka, "Improving Biosensor Analysis", Journal of Mol. Recog., 1999, No. 12, pp.279-284
	Shebuski, et al., "Role of Inflammatory Mediators in Thrombogenesis," JPET, 2002, Vol. 300, No. 3, pp. 729-735
	Wang, et al., "Prevention of Intimal Hyperplasia With Recombinant Soluble P-Selectin Glycoprotein Ligand-Immunoglobulin in the Porcine Coronary Artery Balloon Injury Model," JACC, August 2001, Vol. 38, No. 2, pp. 577-582

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	